We are live on
!
Find out more
TCM
Tang Capital Management Portfolio holdings
AUM
$1.97B
1-Year Est. Return
125.1%
This Fund
S&P 500
This Quarter
Est. Return
+16.47%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.4B
AUM Growth
+$418M
(+43%)
Cap. Flow
+$336M
Cap. Flow
% of AUM
23.99%
Top 10 Holdings %
Top 10 Hldgs %
35.88%
Holding
162
New
35
Increased
43
Reduced
14
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITOS
iTeos Therapeutics
ITOS
|
+$36.7M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
+$30.7M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$27.6M |
| 4 |
Relay Therapeutics
RLAY
|
+$26.7M |
| 5 |
Immunocore
IMCR
|
+$25.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$24.4M |
| 2 |
DVAX
Dynavax Technologies
DVAX
|
+$6.61M |
| 3 |
Beam Therapeutics
BEAM
|
+$2.58M |
| 4 |
CRISPR Therapeutics
CRSP
|
+$2.54M |
| 5 |
Inhibrx
INBX
|
+$2.37M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.59% |
| 2 | Technology | 1.47% |
| 3 | Communication Services | 1.22% |
| 4 | Real Estate | 0.34% |
| 5 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Lexicon Pharmaceuticals
LXRX
$1.1B
| $157K | 0.01% |
+100,000
| New | +$178K |
|
152
Ford
F
$55.7B
| $135K | 0.01% |
12,773
| – | – |
|
|
LVTX
153
DELISTED
LAVA Therapeutics
LVTX
| $88.1K | 0.01% |
53,101
+47,992
| +939% | +$87.8K |
|
|
ALLK
154
DELISTED
Allakos
ALLK
| $29.6K | ﹤0.01% |
+45,262
| New | +$32.8K |
|
|
ADAP
155
DELISTED
Adaptimmune Therapeutics
ADAP
| – | – |
-1,743,619
| Closed | -$1.7M |
|
156
Aligos Therapeutics
ALGS
$34.9M
| – | – |
-66,000
| Closed | -$578K |
|
157
Douglas Emmett
DEI
$1.96B
| – | – |
-171,138
| Closed | -$2.28M |
|
158
Journey Medical
DERM
$177M
| – | – |
-148,322
| Closed | -$837K |
|
|
159
Inhibrx
INBX
$1.3B
| – | – |
-167,500
| Closed | -$2.37M |
|
|
160
Eli Lilly
LLY
$1.06T
| – | – |
-27,000
| Closed | -$24.4M |
|
|
MOLN
161
Molecular Partners
MOLN
| – | – |
-2,500
| Closed | -$18.1K |
|
162
Quince Therapeutics
QNCX
$29.5M
| – | – |
-7,500
| Closed | -$1.13M |
|
Similar funds
HA
NIM
RMCM
FC
SC
CAM
BC
FFH
Tang Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Tang Capital Management held 162 positions worth $1.4B, up 43% from $982M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Tang Capital Management deployed $336M of net new capital in Q3 2024, opening 35 new positions and adding to 43 existing holdings. Its largest new stake was iTeos Therapeutics: 2,407,800 shares worth $24.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Dynavax Technologies, an estimated $6.61M trimmed.
- Tang Capital Management's largest Q3 2024 buy was iTeos Therapeutics: 2,407,800 shares worth $24.6M.
- Tang Capital Management added most to Aurinia Pharmaceuticals in Q3 2024, an estimated $27.6M increase.
- Tang Capital Management's biggest Q3 2024 reduction was Dynavax Technologies, cutting an estimated $6.61M.
- Tang Capital Management fully exited Eli Lilly in Q3 2024, selling an estimated $24.4M.
- Tang Capital Management's ten largest holdings make up 36% of its $1.4B portfolio in Q3 2024.
- Tang Capital Management opened 35 new positions and closed 8 in Q3 2024.
- Tang Capital Management's portfolio value rose 43% quarter-over-quarter to $1.4B.
Based on Tang Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.